Reviewing Infinity Pharmaceuticals Inc. (INFI)’s and Ascendis Pharma A/S (NASDAQ:ASND)’s results

We are comparing Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Ascendis Pharma A/S (NASDAQ:ASND) on their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Infinity Pharmaceuticals Inc. 22.15M 4.62 11.25M 1.25 1.28
Ascendis Pharma A/S N/A 0.00 N/A -3.81 0.00

In table 1 we can see Infinity Pharmaceuticals Inc. and Ascendis Pharma A/S’s top-line revenue, earnings per share and valuation.


Table 2 demonstrates the return on equity, return on assets and net margins of Infinity Pharmaceuticals Inc. and Ascendis Pharma A/S.

Net Margins Return on Equity Return on Assets
Infinity Pharmaceuticals Inc. -50.79% -20.8% -18.2%
Ascendis Pharma A/S 0.00% -45.2% -41.3%

Volatility & Risk

Infinity Pharmaceuticals Inc. has a beta of 2.22 and its 122.00% more volatile than Standard and Poor’s 500. Ascendis Pharma A/S has a 0.91 beta and it is 9.00% less volatile than Standard and Poor’s 500.


The Current Ratio and Quick Ratio of Infinity Pharmaceuticals Inc. are 10.7 and 10.7 respectively. Its competitor Ascendis Pharma A/S’s Current Ratio is 10.5 and its Quick Ratio is 10.5. Infinity Pharmaceuticals Inc. can pay off short and long-term obligations better than Ascendis Pharma A/S.

Analyst Ratings

Infinity Pharmaceuticals Inc. and Ascendis Pharma A/S Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Infinity Pharmaceuticals Inc. 1 1 1 2.33
Ascendis Pharma A/S 0 0 5 3.00

Infinity Pharmaceuticals Inc. has a 66.67% upside potential and a consensus price target of $3. Ascendis Pharma A/S on the other hand boasts of a $153.8 average price target and a 19.98% potential upside. The information presented earlier suggests that Infinity Pharmaceuticals Inc. looks more robust than Ascendis Pharma A/S as far as analyst view.

Insider & Institutional Ownership

Roughly 54.9% of Infinity Pharmaceuticals Inc. shares are held by institutional investors while 95.7% of Ascendis Pharma A/S are owned by institutional investors. About 1.1% of Infinity Pharmaceuticals Inc.’s share are held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Infinity Pharmaceuticals Inc. -3.03% 32.23% 16.79% -21.57% -16.67% 35.59%
Ascendis Pharma A/S 61.55% 68.77% 97.38% 58.5% 89.47% 92.5%

For the past year Infinity Pharmaceuticals Inc. was less bullish than Ascendis Pharma A/S.


Infinity Pharmaceuticals Inc. beats on 8 of the 12 factors Ascendis Pharma A/S.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.